Epifix denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epifix are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied EpiFix: Non-Formulary

EpiFix (dehydrated human amnion/chorion membrane allograft) is a regenerative wound care product, and BCBS has denied coverage on the basis that it is not included in the plan's formulary or preferred product list. Non-formulary denials for wound care products like EpiFix are common because these products sit in a category — tissue allografts and skin substitutes — where formulary management varies widely across plans. A non-formulary denial does not mean the product is not medically appropriate; it means it requires an additional step to obtain coverage through a formulary exception.

## Why This Denial Is Appealable

All non-grandfathered health plans subject to ACA requirements must have a formulary exception process. If EpiFix is medically necessary for your specific wound and no formulary alternative is clinically appropriate, you are entitled to request a formulary exception. The appeal should document why preferred alternatives are inadequate, not available, or have already been tried and failed for your wound type.

## Your Federal Appeal Rights

• Internal appeal / Formulary exception: Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal review. File the formulary exception request and appeal simultaneously within the deadline in your denial letter.
• External review: If the internal appeal and formulary exception are denied, escalate to an Independent Review Organization (IRO) within approximately four months of exhausting internal remedies.
• Expedited review: Request expedited processing if your wound is acutely worsening, infected, or poses risk of serious harm.

## Documentation to Gather

• Wound diagnosis and history: Records documenting your wound type, duration, and severity from your treating physician or wound care specialist.
• Prior treatment history with dates and outcomes: Documentation showing what wound care products and treatments you have already tried, including any formulary-preferred alternatives BCBS might suggest, with dates and outcomes.
• Prescriber letter addressing formulary alternatives: A letter from your prescriber explaining why any formulary-preferred wound care product is not clinically appropriate for your specific wound — addressing each preferred alternative specifically.
• Medical-necessity narrative: Your prescriber's clinical justification for EpiFix given your wound type, severity, and treatment history.

## Criteria-Mapping Structure

Request BCBS's formulary exception criteria and the list of formulary-preferred wound care alternatives they would require you to try. For each exception criterion, document your response:

| Formulary Exception Criterion | Supporting Evidence | |---|---| | Formulary alternatives tried and failed | Treatment history records with dates and documented outcomes | | Formulary alternatives clinically inappropriate | Prescriber letter explaining why each preferred alternative is not suitable | | Medical necessity of EpiFix specifically | Prescriber medical-necessity letter | | Qualifying wound type and severity | Physician records with wound measurements and staging |

Also request BCBS's published medical policy for skin substitutes and tissue allografts, as the formulary exception criteria may reference that policy's clinical coverage requirements, which you will need to address in parallel.